Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Transplantation and Cellular Therapy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles